Antibacterial and Anti-virulence Activity of the Repurposed Agent SX-682 Against Staphylococcus aureus
Ontology highlight
ABSTRACT:
ORGANISM(S): Staphylococcus Aureus Subsp. Aureus Nctc 8325
SUBMITTER: 
Zhijian Yu
PROVIDER: PXD072538 | iProX | Wed Dec 31 00:00:00 GMT 2025
REPOSITORIES: iProX
Similar Datasets
Project description:Staphylococcus aureus (S. aureus) is one of the most dominant human pathogen, responsible for a variety of chronic and severe infections. As a classic traditional Chinese medicine (TCM) formula, Epidemic Prevention Sachets have been used clinically for centuries to treat infectious diseases. The antimicrobial activity of the essential oil (EO) from Epidemic Prevention Sachets against the S. aureus has not been investigated. In this study, the EO was tested for its antimicrobial activity against S. aureus. We identified that the EOs has high activity against S. aureus. It showed higher activity than the known antibacterial drug combination of Penicillin streptomycin. The same results were demonstrated by transmission electron microscopy. The impact of the EO on transcription of genes from S. aureus was analyzed. SAOUHSC_01002, SAOUHSC_02444, SAOUHSC_00282 and SAOUHSC_00325, which are involved in cation transport (GO:0006812), were significantly affected by the essential oil as defined in the Gene Ontology Biological Process (GO BP), whereas SAOUHSC_00114 and SAOUHSC_03000, which are involved in the protein tyrosine kinase modulator pathway (K19420), were significantly enriched in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. Analysis of clusters of orthologous groups (COG) found that there are differences in multiple metabolic pathways, mainly including secondary biosynthesis metabolism, biofilm related genes and energy metabolism. Our study indicates that the essential oil from Epidemic Prevention Sachets is an effective herbal formula against S. aureus.
2025-05-17 | GSE296946 | GEO
Project description:In the present study, we employed Affymetrix Staphylococcus aureus GeneChip arrays to investigate the dynamics of global gene expression profiles during the cellular response of Staphylococcus aureus to hypochlorite, which involved initial growth inhibition and subsequent partial recovery. Keywords: Time course
2007-08-01 | GSE5498 | GEO
Project description:Staphylococcus aureus is a major human pathogen and resistant to numerous clinically used antibiotics. The first antibiotic developed for S. aureus infections was the nonribosomal petide secondary metabolite penicillin. We discovered cryptic nonribosomal peptide secondary metabolites, the aureusimines, made by S. aureus itself that are not antibiotics, but function as small molecule regulators of virulence factor expression. Using established rules and codes for nonribosomal peptide assembly we predicted these nonribosomal peptides, and used these predictions to identify them from S. aureus culture broths. Functional studies using global microarray and mouse bacteremia models established that the aureusimines control virulence factor expression and are necessary for productive infections. This is the first report of the aureusimines and has important implications for the treatment of drug resistant S. aureus. Targeting aureusimine synthesis may provide novel anti-infectives.
2010-07-01 | GSE21373 | GEO
Project description:Staphylococcus aureus is one of the most important pathogens in humans and animals, multiply resistant strains are increasingly widespread, new agents are needed for the treatment of S. aureus. Rhein, a natural plant product, has potential antimicrobial activity against Staphylococcus aureus. We employed Affymetrix Staphylococcus aureus GeneChipsTM arrays to investigate the global transcriptional profiling of Staphylococcus aureus ATCC25923 treated with rhein. Results provided insight into mechanisms involved in rhein - Staphylococcus aureus interactions. Keywords: rhein response
2007-06-15 | GSE8135 | GEO
Project description:Staphylococcus aureus is a major human pathogen and resistant to numerous clinically used antibiotics. The first antibiotic developed for S. aureus infections was the nonribosomal petide secondary metabolite penicillin. We discovered cryptic nonribosomal peptide secondary metabolites, the aureusimines, made by S. aureus itself that are not antibiotics, but function as small molecule regulators of virulence factor expression. Using established rules and codes for nonribosomal peptide assembly we predicted these nonribosomal peptides, and used these predictions to identify them from S. aureus culture broths. Functional studies using global microarray and mouse bacteremia models established that the aureusimines control virulence factor expression and are necessary for productive infections. This is the first report of the aureusimines and has important implications for the treatment of drug resistant S. aureus. Targeting aureusimine synthesis may provide novel anti-infectives. Commerically available S. aureus GeneChips (Affymetrix) were used to compare biological replicates of early and late exponential phase wild type (Newman) and aureusimine defective (ausA) organisms.
2010-07-30 | E-GEOD-21373 | biostudies-arrayexpress
Project description:Staphylococcus aureus (S. aureus) is an important human and animal pathogen, multiply resistant strains are increasingly widespread, new agents are needed for the treatment of S. aureus. magnolol has potent antimicrobial activity against S. aureus. We employed Affymetrix Staphylococcus aureus GeneChipsTM arrays to investigate the global transcriptional profiling of Staphylococcus aureus ATCC25923 treated with magnolol. Keywords: gene expression array-based, count
2008-10-22 | GSE13236 | GEO
Project description:Staphylococcus aureus (S. aureus) is an important human and animal pathogen, multiply resistant strains are increasingly widespread, new agents are needed for the treatment of S. aureus. eugenol, a natural plant product, has potent antimicrobial activity against S. aureus. We employed Affymetrix Staphylococcus aureus GeneChipsTM arrays to investigate the global transcriptional profiling of Staphylococcus aureus ATCC25923 treated with eugenol. Keywords: gene expression array-based, count
2007-08-10 | GSE8735 | GEO
Project description:Staphylococcus aureus (S. aureus) is an important human and animal pathogen, multiply resistant strains are increasingly widespread, new agents are needed for the treatment of S. aureus. Cryptotanshinone, a natural plant product, has potent antimicrobial activity against S. aureus. We employed Affymetrix Staphylococcus aureus GeneChipsTM arrays to investigate the global transcriptional profiling of Staphylococcus aureus ATCC25923 treated with cryptotanshinone. Keywords: gene expression array-based, count
2008-10-16 | GSE13203 | GEO
Project description:Young adult fer-15;fem-1 Caenorhabditis elegans were infected with Staphylococcus aureus for 8 h to determine the transcriptional host response to Staphylococcus aureus. Analysis of differential gene expression in C. elegans young adults exposed to two different bacteria: E. coli strain OP50 (control), wild-type Staphylococcus aureus RN6390. Samples were analyzed at 8 hours after exposure to the different bacteria. These studies identified C. elegans genes induced by pathogen infection. Keywords: response to pathogen infection, innate immunity, host-pathogen interactions
2010-06-12 | GSE21819 | GEO
Project description:Lomitapide has been approved by FDA for years in reducing levels of low-density lipoprotein (LDL) in cases of familial hypercholesterolemia, whereas the antibacterial effect of lomitapide remains elusive. In this study, the inhibitory activities of lomitapide against Staphylococcus aureus, including both methicillin sensitive and resistant S. aureus, were first time discovered by drug repositioning. Lomitapide has shown the inhibitory activities not only on the planktonic cell growth but also on the biofilm formation of S. aureus. Moreover, lomitapide has shown mild bactericidal effect on planktonic cells of clinical S. aureus strains as indicated in time killing assay. In order to investigate the mechanism of actions of lomitapide, quantitative proteomics analysis was then applied and suggested that the pathways involved in the cell wall biosynthesis and protein biosynthesis might participate in its action mode, whereas the clinical applications of lomitapide antibacterial activities need to be extensive investigated.
2022-03-29 | PXD031706 | Pride